Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase

BACKGROUND: Imatinib is a tyrosine kinase inhibitor that is used to treat chronic myelogenous leukemia (CML). BCR-ABL mutations are associated with failure of imatinib treatment in many CML patients. LYN kinase regulates survival and responsiveness of CML cells to inhibition of BCR-ABL kinase, and d...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Wu, Ji, Meng, Feng, Kong, Ling-Yuan, Peng, Zhenghong, Ying, Yunming, Bornmann, William G., Darnay, Bryant G., Lamothe, Betty, Sun, Hanshi, Talpaz, Moshe, Donato, Nicholas J.
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2008
Témata:
Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2902818/
https://ncbi.nlm.nih.gov/pubmed/18577747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jnci/djn188
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky